EMA reviews rosiglitazone-containing medicines

Friday 9 July 2010

The European Medicines Agency has announced a review of rosiglitazone-containing medicines for diabetes following new safety data. The review will decide whether or not the marketing authorisations of the drugs should be revoked, suspended or changed.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom